Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders

Kenshi Takechi, Yurika Yoshioka, Hitoshi Kawazoe, Mamoru Tanaka, Shingo Takatori, Miwako Kobayashi, Ichiro Matsuoka, Hiroaki Yanagawa, Yoshito Zamami, Masaki Imanishi, Keisuke Ishizawa, Akihiro Tanaka, Hiroaki Araki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Treatment with antipsychotic drugs has been associated with hyperprolactinemia. The same antipsychotic drugs have also been associated with side effects such as menstruation disorders. The aim of this study was to evaluate the prevalence of hyperprolactinemia and menstruation disorders in women undergoing antipsychotic treatment. We performed a retrospective chart review study of psychiatric patients who underwent laboratory testing for serum prolactin (PRL) level between March 2011 and March 2015 in Ehime University Hospital. Patients presenting with and without menstruation disorders were evaluated to determine if they presented concomitant hyperprolactinemia. Patients with menstrual disorders had a significant increase in serum PRL level with a mean of approximately 90ng/mL. Those with menstrual disorders presented increased PRL levels by 2-fold that of patients without menstrual disorder. However, there was no significant difference in the equivalent dose of chlorpromazine between these two groups. Additionally, about 70% of patients with menstrual disorders received risperidone treatment. The receiver operating characteristic curve showed that the optimal cutoff point of serum PRL level associated with the development of menstrual disorders was 60ng/mL. Based on these results, we concluded that patients with menstrual disorders presented increased serum PRL, and that most of them underwent treatment with risperidone.

Original languageEnglish
Pages (from-to)1775-1778
Number of pages4
JournalBiological and Pharmaceutical Bulletin
Volume40
Issue number10
DOIs
Publication statusPublished - 2017 Jan 1
Externally publishedYes

Fingerprint

Menstruation Disturbances
Hyperprolactinemia
Antipsychotic Agents
Psychiatry
Prolactin
Risperidone
Serum
Chlorpromazine
Therapeutics
ROC Curve

Keywords

  • Antipsychotic drug
  • Menstruation
  • Prolactin

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders. / Takechi, Kenshi; Yoshioka, Yurika; Kawazoe, Hitoshi; Tanaka, Mamoru; Takatori, Shingo; Kobayashi, Miwako; Matsuoka, Ichiro; Yanagawa, Hiroaki; Zamami, Yoshito; Imanishi, Masaki; Ishizawa, Keisuke; Tanaka, Akihiro; Araki, Hiroaki.

In: Biological and Pharmaceutical Bulletin, Vol. 40, No. 10, 01.01.2017, p. 1775-1778.

Research output: Contribution to journalArticle

Takechi, K, Yoshioka, Y, Kawazoe, H, Tanaka, M, Takatori, S, Kobayashi, M, Matsuoka, I, Yanagawa, H, Zamami, Y, Imanishi, M, Ishizawa, K, Tanaka, A & Araki, H 2017, 'Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders', Biological and Pharmaceutical Bulletin, vol. 40, no. 10, pp. 1775-1778. https://doi.org/10.1248/bpb.b17-00053
Takechi, Kenshi ; Yoshioka, Yurika ; Kawazoe, Hitoshi ; Tanaka, Mamoru ; Takatori, Shingo ; Kobayashi, Miwako ; Matsuoka, Ichiro ; Yanagawa, Hiroaki ; Zamami, Yoshito ; Imanishi, Masaki ; Ishizawa, Keisuke ; Tanaka, Akihiro ; Araki, Hiroaki. / Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders. In: Biological and Pharmaceutical Bulletin. 2017 ; Vol. 40, No. 10. pp. 1775-1778.
@article{cc80564ec95147c39586a9c1421e442d,
title = "Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders",
abstract = "Treatment with antipsychotic drugs has been associated with hyperprolactinemia. The same antipsychotic drugs have also been associated with side effects such as menstruation disorders. The aim of this study was to evaluate the prevalence of hyperprolactinemia and menstruation disorders in women undergoing antipsychotic treatment. We performed a retrospective chart review study of psychiatric patients who underwent laboratory testing for serum prolactin (PRL) level between March 2011 and March 2015 in Ehime University Hospital. Patients presenting with and without menstruation disorders were evaluated to determine if they presented concomitant hyperprolactinemia. Patients with menstrual disorders had a significant increase in serum PRL level with a mean of approximately 90ng/mL. Those with menstrual disorders presented increased PRL levels by 2-fold that of patients without menstrual disorder. However, there was no significant difference in the equivalent dose of chlorpromazine between these two groups. Additionally, about 70{\%} of patients with menstrual disorders received risperidone treatment. The receiver operating characteristic curve showed that the optimal cutoff point of serum PRL level associated with the development of menstrual disorders was 60ng/mL. Based on these results, we concluded that patients with menstrual disorders presented increased serum PRL, and that most of them underwent treatment with risperidone.",
keywords = "Antipsychotic drug, Menstruation, Prolactin",
author = "Kenshi Takechi and Yurika Yoshioka and Hitoshi Kawazoe and Mamoru Tanaka and Shingo Takatori and Miwako Kobayashi and Ichiro Matsuoka and Hiroaki Yanagawa and Yoshito Zamami and Masaki Imanishi and Keisuke Ishizawa and Akihiro Tanaka and Hiroaki Araki",
year = "2017",
month = "1",
day = "1",
doi = "10.1248/bpb.b17-00053",
language = "English",
volume = "40",
pages = "1775--1778",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "10",

}

TY - JOUR

T1 - Psychiatric patients with antipsychotic drug-induced hyperprolactinemia and menstruation disorders

AU - Takechi, Kenshi

AU - Yoshioka, Yurika

AU - Kawazoe, Hitoshi

AU - Tanaka, Mamoru

AU - Takatori, Shingo

AU - Kobayashi, Miwako

AU - Matsuoka, Ichiro

AU - Yanagawa, Hiroaki

AU - Zamami, Yoshito

AU - Imanishi, Masaki

AU - Ishizawa, Keisuke

AU - Tanaka, Akihiro

AU - Araki, Hiroaki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Treatment with antipsychotic drugs has been associated with hyperprolactinemia. The same antipsychotic drugs have also been associated with side effects such as menstruation disorders. The aim of this study was to evaluate the prevalence of hyperprolactinemia and menstruation disorders in women undergoing antipsychotic treatment. We performed a retrospective chart review study of psychiatric patients who underwent laboratory testing for serum prolactin (PRL) level between March 2011 and March 2015 in Ehime University Hospital. Patients presenting with and without menstruation disorders were evaluated to determine if they presented concomitant hyperprolactinemia. Patients with menstrual disorders had a significant increase in serum PRL level with a mean of approximately 90ng/mL. Those with menstrual disorders presented increased PRL levels by 2-fold that of patients without menstrual disorder. However, there was no significant difference in the equivalent dose of chlorpromazine between these two groups. Additionally, about 70% of patients with menstrual disorders received risperidone treatment. The receiver operating characteristic curve showed that the optimal cutoff point of serum PRL level associated with the development of menstrual disorders was 60ng/mL. Based on these results, we concluded that patients with menstrual disorders presented increased serum PRL, and that most of them underwent treatment with risperidone.

AB - Treatment with antipsychotic drugs has been associated with hyperprolactinemia. The same antipsychotic drugs have also been associated with side effects such as menstruation disorders. The aim of this study was to evaluate the prevalence of hyperprolactinemia and menstruation disorders in women undergoing antipsychotic treatment. We performed a retrospective chart review study of psychiatric patients who underwent laboratory testing for serum prolactin (PRL) level between March 2011 and March 2015 in Ehime University Hospital. Patients presenting with and without menstruation disorders were evaluated to determine if they presented concomitant hyperprolactinemia. Patients with menstrual disorders had a significant increase in serum PRL level with a mean of approximately 90ng/mL. Those with menstrual disorders presented increased PRL levels by 2-fold that of patients without menstrual disorder. However, there was no significant difference in the equivalent dose of chlorpromazine between these two groups. Additionally, about 70% of patients with menstrual disorders received risperidone treatment. The receiver operating characteristic curve showed that the optimal cutoff point of serum PRL level associated with the development of menstrual disorders was 60ng/mL. Based on these results, we concluded that patients with menstrual disorders presented increased serum PRL, and that most of them underwent treatment with risperidone.

KW - Antipsychotic drug

KW - Menstruation

KW - Prolactin

UR - http://www.scopus.com/inward/record.url?scp=85030761013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030761013&partnerID=8YFLogxK

U2 - 10.1248/bpb.b17-00053

DO - 10.1248/bpb.b17-00053

M3 - Article

VL - 40

SP - 1775

EP - 1778

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 10

ER -